Given that Garvin and colleagues (Garvin et al., 2020) have documented decreased expression of ACE and neprilysin in COVID‐19 patients, and expected elevated levels of bradykinin (i.e. inefficient degradation of the peptide), then it is likely that the expression of Nln is also decreased in these patients (otherwise, it could efficiently inactivate bradykinin). This evidence concerns the gene NLN and COVID-19.